BeiGene
BGNE
#963
Rank
S$27.14 B
Marketcap
$239.18
Share price
1.02%
Change (1 day)
1.82%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.80

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$22.55. In 2022 the company made an earnings per share (EPS) of -$26.25 a decrease over its 2021 EPS that were of -$20.61.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.80-13.12%
2022-$26.2527.35%
2021-$20.61-19.96%
2020-$25.7520.81%
2019-$21.3231.52%
2018-$16.21417.57%
2017-$3.13-37.16%
2016-$4.98158.95%
2015-$1.92

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.36-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.37-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA